In a study of 851 patients with metastatic non-clear cell RCC,
researchers found that patients who underwent cytoreductive nephrectomy had a
significant 62% decreased risk of CSM than those who did not, according to
results published online ahead of print in European Urology Focus.

The 2-year cumulative CSM rate was 52.6% for those who underwent cytoreductive
nephrectomy group versus 77.7% for those who did not. The
investigators observed a survival benefit of cytoreductive nephrectomy across
histologic subtypes (papillary, chromophobe, collecting duct carcinoma).

Among contemporary patients (those diagnosed during 2010–2014),
cytoreductive nephrectomy was associated with a 68% decreased risk of CSM.

Of the 851 patients, 67.6% underwent cytoreductive nephrectomy. The
study population had a median age of 62 years and a median tumor size of 80 mm;
74.4% were men and 71.4% were white. Overall, 555 patients died during the
study period.